SELLAS Life Sciences Group, Inc. (SLS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 4M 8M 12M Q4 '12: 7.6M Q1 '13: 4.8M Q2 '13: 1.4M Q3 '13: 2.6M Q4 '13: 2.6M Q1 '14: 4.8M Q2 '14: 7.1M Q3 '14: 7.6M Q4 '14: 9.3M Q1 '15: 9.9M Q2 '15: 10.9M Q4 '20: 1.9M Q1 '21: 7.6M Q2 '21: 9.5M Q3 '21: 9.5M Q4 '21: 7.6M Q1 '22: 2.9M Q2 '22: 1M Q3 '22: 1M Q4 '22: 1M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q2 '13 Q1 '14 Q4 '14 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Gross Profit TTM

0 3M 6M 9M Q4 '12: 6.5M Q1 '13: 6.5M Q2 '13: 6.5M Q3 '13: 7.4M Q4 '13: 7.4M Q4 '12 Q1 '13 Q2 '13 Q3 '13 Q4 '13

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q4 '13: -28.5M Q1 '14: -33.7M Q2 '14: -41.5M Q3 '14: -45.2M Q4 '14: -47.9M Q1 '15: -45M Q2 '15: -38.3M Q3 '15: -36.3M Q4 '15: -34.2M Q1 '16: -34.3M Q2 '16: -34.5M Q3 '16: -32.3M Q4 '16: -16M Q1 '17: -12.1M Q2 '17: -7.7M Q3 '17: -5.7M Q4 '17: -23M Q4 '20: -17M Q1 '21: -15.2M Q2 '21: -15.3M Q3 '21: -17.8M Q4 '21: -25.3M Q1 '22: -39.8M Q2 '22: -44M Q3 '22: -44.1M Q4 '22: -42M Q1 '23: -36.5M Q2 '23: -36.9M Q3 '23: -39.1M Q4 '23: -37.9M Q1 '24: -36.2M Q2 '24: -34.8M Q3 '24: -32.8M Q4 '24: -31.5M Q1 '25: -27.9M Q2 '25: -27.2M Q3 '25: -26.9M Q4 '25: -28.3M Q1 '26: -31.5M Q2 '26: -35.2M Q4 '14 Q1 '16 Q2 '17 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '16: -37.7M Q4 '16: -17.7M Q1 '17: -5.8M Q2 '17: -17.1M Q3 '17: -14.6M Q4 '17: -23.8M Q1 '18: -27.1M Q2 '18: -27.3M Q3 '18: -23.1M Q4 '18: -27.7M Q1 '19: -24.2M Q2 '19: -21.3M Q3 '19: -25.2M Q4 '19: -19.3M Q1 '20: -18.9M Q2 '20: -20.2M Q3 '20: -20.5M Q4 '20: -16.8M Q1 '21: -15M Q2 '21: -15.2M Q3 '21: -17.8M Q4 '21: -20.7M Q1 '22: -35M Q2 '22: -38.8M Q3 '22: -38.8M Q4 '22: -41.3M Q1 '23: -35.7M Q2 '23: -36.1M Q3 '23: -38.3M Q4 '23: -37.3M Q1 '24: -35.8M Q2 '24: -34.4M Q3 '24: -32.3M Q4 '24: -30.9M Q1 '25: -27.1M Q2 '25: -26.3M Q3 '25: -25.9M Q4 '25: -26.9M Q1 '26: -29.5M Q2 '26: -32.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 600K 1.2M 1.8M Q2 '13: 0 Q3 '13: 258K Q4 '13: 520K Q1 '14: 851K Q2 '14: 1.2M Q3 '14: 1.2M Q4 '14: 1.4M Q1 '15: 1.5M Q2 '15: 1.6M Q4 '20: 0 Q1 '21: 100K Q2 '21: 200K Q3 '21: 200K Q4 '21: 200K Q1 '22: 200K Q2 '22: 100K Q3 '22: 100K Q4 '22: 100K Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q1 '14 Q1 '15 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '16: -52.2M Q4 '16: -42.4M Q1 '17: -33M Q2 '17: -24.5M Q3 '17: -14.7M Q4 '17: -11M Q1 '18: -12.6M Q2 '18: -15.8M Q3 '18: -27.6M Q4 '18: -30.4M Q1 '19: -30M Q2 '19: -28.4M Q3 '19: -18M Q4 '19: -17.6M Q1 '20: -19.5M Q2 '20: -18.2M Q3 '20: -18M Q4 '20: -10.4M Q1 '21: -13.9M Q2 '21: -15.4M Q3 '21: -17.6M Q4 '21: -26M Q1 '22: -22.9M Q2 '22: -23.8M Q3 '22: -23.6M Q4 '22: -23.8M Q1 '23: -28.8M Q2 '23: -30.6M Q3 '23: -31.7M Q4 '23: -31.4M Q1 '24: -30M Q2 '24: -32.2M Q3 '24: -33.1M Q4 '24: -35.4M Q1 '25: -33.7M Q2 '25: -31.4M Q3 '25: -30.6M Q4 '25: -28.4M Q1 '26: -28.2M Q2 '26: -28.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q2 '11: -11.3M Q3 '11: -12.5M Q4 '11: -14.7M Q1 '12: -16.5M Q2 '12: -19.2M Q3 '12: -20M Q4 '12: -21M Q1 '13: -21.4M Q2 '13: -22.2M Q3 '13: -26.2M Q4 '13: -29.2M Q1 '14: -32M Q2 '14: -37.6M Q3 '14: -40.8M Q4 '14: -42.9M Q1 '15: -46.4M Q2 '15: -45.3M Q3 '15: -43.7M Q4 '15: -48.3M Q1 '16: -50M Q2 '16: -49.6M Q3 '16: -52.3M Q4 '16: -42.4M Q3 '11 Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '12: 67.2M Q2 '13: 83.7M Q2 '15: 161.4M Q2 '16: 9.3M Q2 '17: 37.4M Q2 '20: 6.7M Q3 '20: 8.4M Q1 '21: 14.9M Q2 '21: 15.3M Q3 '21: 15.9M Q1 '22: 15.9M Q2 '22: 20.3M Q3 '22: 20.6M Q1 '23: 23.5M Q2 '23: 28.3M Q3 '23: 28.4M Q1 '24: 44.8M Q2 '24: 57.6M Q3 '24: 68.3M Q1 '25: 87.8M Q2 '25: 98.6M Q3 '25: 108.4M Q1 '26: 172.5M Q2 '26: 189.2M Q2 '15 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-75.00 -50.00 -25.00 0.00 25.00 50.00 75.00 Q3 '14: -0.76 Q4 '14: -6.13 Q1 '15: -6.19 Q2 '15: -6.12 Q3 '15: -6.18 Q4 '17: -12.00 Q1 '18: -10.04 Q2 '18: -11.08 Q3 '18: -35.56 Q4 '18: -49.97 Q1 '19: -59.42 Q2 '19: -64.49 Q3 '19: -40.42 Q4 '19: -10.92 Q1 '20: -0.46 Q2 '20: 5.21 Q3 '20: 7.36 Q4 '20: -2.13 Q1 '21: -1.63 Q2 '21: -1.27 Q3 '21: -1.19 Q4 '21: -1.33 Q1 '22: -2.22 Q2 '22: -2.33 Q3 '22: -2.22 Q4 '22: -2.23 Q1 '23: -1.65 Q2 '23: -1.55 Q3 '23: -1.54 Q4 '23: -1.36 Q1 '24: -1.10 Q2 '24: -0.92 Q3 '24: -0.69 Q4 '24: -0.52 Q1 '25: -0.38 Q2 '25: -0.32 Q3 '25: -0.28 Q4 '25: -0.25 Q1 '26: -0.23 Q2 '26: -0.21 Q3 '15 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.